Estrogen receptor (ER) and progesterone receptor (PR) retest rate in breast ductal carcinoma in situ (DCIS) surgical excision specimens.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e18524
Abstract: e18524Background: ER testing in breast DCIS identifies patients who benefit from endocrine manipulation. We hypothesized that ER and PR testing on both biopsy and surgical tumor specimen may increa... read more here.
Keywords: retest rate; progesterone receptor; receptor progesterone; receptor ... See more keywords